This trial studies how well the combination of binimetinib and encorafenib works in treating patients with pancreatic cancer that has a specific genetic mutation. These medications aim to stop cancer cells from growing by blocking certain enzymes they need. The trial targets patients whose cancer may not respond well to usual treatments. Encorafenib and binimetinib have shown substantial antitumor activity in melanoma, particularly in combination therapy.